Niagen Bioscience Dirección
Dirección controles de criterios 2/4
El CEO de Niagen Bioscience es Rob Fried , nombrado en Jun 2018, tiene una permanencia de 7.92 años. compensación anual total es $8.38M, compuesta por 7.7% salario y 92.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.09% de las acciones de la empresa, por valor de $6.25M. La antigüedad media del equipo directivo y de la junta directiva es de 6.3 años y 9 años, respectivamente.
Información clave
Rob Fried
Chief Executive Officer (CEO)
US$8.4m
Compensación total
| Porcentaje del salario del CEO | 7.71% |
| Permanencia del CEO | 7.9yrs |
| Participación del CEO | 2.1% |
| Permanencia media de la dirección | 6.3yrs |
| Promedio de permanencia en la Junta Directiva | 9yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • May 14
NAGE: Core Demand And Injectables Will Drive Future Upside Potential
Niagen Bioscience's analyst price target has shifted from $13.60 to $12.60, as analysts adjust their models to slightly lower revenue growth, profit margin, and fair value assumptions while still highlighting ongoing demand in the core business and potential upside from the injectable segment. Analyst Commentary Recent research updates show a consistent pattern of price target reductions, with the latest move taking the blended target to US$12.60.Actualización de narrativa • Apr 22
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that point to steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Recent commentary around Niagen Bioscience centers on how updated Q4 models affect the risk and reward trade off, with attention on both the established core business and the injectable opportunity.Actualización de narrativa • Apr 07
NAGE: Core Strength And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that reflect steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Analysts see the updated price target as largely reflecting model clean up after Q4, rather than a shift in the overall view on the business.Actualización de narrativa • Mar 23
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14. This reflects updated models after Q4 results that pointed to steady demand in the core business and potential upside from the injectable segment.Actualización de narrativa • Mar 06
NAGE: Core Demand And Injectables Outlook Will Support Future Upside
Analysts have trimmed their 12 month price target on Niagen Bioscience from $16.04 to $13.60, citing updated models that reflect steady demand in the core business, potential upside in injectables, adjustments to revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to steady demand in the core business as a key support for current valuation, suggesting the updated models still see the existing portfolio as a meaningful earnings driver.Seeking Alpha • Nov 15
Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years
Summary Niagen Bioscience delivered record Q3 revenue, rising 33% year-over-year, driven by strong Tru Niagen demand and accelerating distribution partnerships. Gross margin expanded to 64.5%, while operating income and adjusted EBITDA grew sharply, reflecting improving scale and cost discipline. Cash from operations already exceeded last year’s total, supporting a new $10 million share repurchase program. The FDA’s reversal on NMN introduces meaningful uncertainty for future demand and competitive dynamics in the NAD+ category. Niagen Bioscience remains financially strong, but sustained momentum in a post-NMN market is unproven, warranting a hold rating. Read the full article on Seeking AlphaArtículo de análisis • Nov 11
We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve
Even though Niagen Bioscience, Inc. ( NASDAQ:NAGE ) posted strong earnings, investors appeared to be underwhelmed. We...Artículo de análisis • Nov 07
Niagen Bioscience, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) just released its quarterly report and things are looking bullish. The company...Artículo de análisis • Oct 03
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues
To the annoyance of some shareholders, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares are down a considerable 25% in...Nueva narrativa • Aug 25
Wellness Adoption And Academic Trials Will Define Future Opportunity
Key Takeaways Expanding clinical credibility and global partnerships are opening new high-margin markets, broadening channels, and supporting scalable revenue growth with improved margins. Strong e-commerce performance and diversified product pipeline in preventive health provide resilience, reduced risk, and durable long-term earnings visibility.Actualización de narrativa • Aug 08
Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
Upward revisions to Niagen Bioscience's price target reflect positive clinical trial results confirming both safety and significant efficacy of its NAD+ supplementation, increased market confidence, and ongoing product and sales momentum, resulting in a higher consensus analyst price target rising from $14.90 to $15.84. Analyst Commentary Positive clinical study results published in a peer-reviewed journal demonstrated that Niagen Bioscience’s NAD+ supplementation is safe for patients with Werner syndrome and achieved a ~140% increase in blood NAD+ levels, along with improvements in liver, kidney, and arterial health markers.Artículo de análisis • Aug 08
Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...Artículo de análisis • Aug 06
What You Can Learn From Niagen Bioscience, Inc.'s (NASDAQ:NAGE) P/S After Its 28% Share Price Crash
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...Artículo de análisis • Jun 17
Market Participants Recognise Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Revenues Pushing Shares 29% Higher
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares have continued their recent momentum with a 29% gain in the last month...Artículo de análisis • May 10
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
A week ago, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) came out with a strong set of first-quarter numbers that could...Artículo de análisis • Apr 05
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues
The Niagen Bioscience, Inc. ( NASDAQ:NAGE ) share price has softened a substantial 30% over the previous 30 days...Artículo de análisis • Mar 29
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE)
Key Insights Niagen Bioscience's estimated fair value is US$7.18 based on 2 Stage Free Cash Flow to Equity Niagen...
Nueva narrativa • Feb 09
NIAGEN IV Expansion And FDA Approvals Will Unlock Future Opportunities
Expansion in clinics and strategic partnerships support revenue growth through increased e-commerce and pharmaceutical-grade product sales.Artículo de análisis • Nov 07
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors
ChromaDex Corporation's ( NASDAQ:CDXC ) strong earnings report was rewarded with a positive stock price move. We did...Artículo de análisis • Nov 05
Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%
Despite an already strong run, ChromaDex Corporation ( NASDAQ:CDXC ) shares have been powering on, with a gain of 70...Artículo de análisis • Jul 25
ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company
Those holding ChromaDex Corporation ( NASDAQ:CDXC ) shares would be relieved that the share price has rebounded 25% in...Artículo de análisis • Jun 15
Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable
Key Insights ChromaDex's Annual General Meeting to take place on 20th of June Total pay for CEO Rob Fried includes...Artículo de análisis • Jun 05
Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump
ChromaDex Corporation ( NASDAQ:CDXC ) shares have retraced a considerable 26% in the last month, reversing a fair...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$19m |
| Dec 31 2025 | US$8m | US$646k | US$17m |
| Sep 30 2025 | n/a | n/a | US$20m |
| Jun 30 2025 | n/a | n/a | US$18m |
| Mar 31 2025 | n/a | n/a | US$14m |
| Dec 31 2024 | US$1m | US$500k | US$9m |
| Sep 30 2024 | n/a | n/a | US$1m |
| Jun 30 2024 | n/a | n/a | -US$1m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$1m | US$500k | -US$5m |
| Sep 30 2023 | n/a | n/a | -US$6m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$1m | US$500k | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$20m |
| Jun 30 2022 | n/a | n/a | -US$28m |
| Mar 31 2022 | n/a | n/a | -US$27m |
| Dec 31 2021 | US$1m | US$500k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$1m | US$519k | -US$20m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$30m |
| Dec 31 2019 | US$2m | US$487k | -US$32m |
Compensación vs. Mercado: La compensación total de Rob($USD8.38M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.72M).
Compensación vs. Ingresos: La compensación de Rob ha aumentado más de un 20% en el último año.
CEO
Rob Fried (65 yo)
7.9yrs
Permanencia
US$8,381,900
Compensación
Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of Niagen Bioscience, Inc. (formerly known as ChromaDex Corporation) since June 22, 2018 and its a Director since July 2015. Mr....
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Chairman | 26.3yrs | US$268.08k | 2.91% $ 8.7m | |
| CEO & Director | 7.9yrs | US$8.38m | 2.09% $ 6.3m | |
| CFO & Principal Accounting Officer | 1.6yrs | US$648.24k | 0.012% $ 36.0k | |
| Senior VP & General Counsel | 1.8yrs | US$558.01k | 0.0028% $ 8.4k | |
| Senior Vice President of Global Regulatory & Scientific Affairs | 6.3yrs | sin datos | sin datos | |
| Chief Marketing Officer | 1.5yrs | sin datos | sin datos | |
| Managing Director of Asia Pacific | 7.6yrs | sin datos | sin datos | |
| Head of Media Relations & Partnerships | no data | sin datos | sin datos | |
| Controller | no data | US$374.47k | 0.28% $ 837.6k | |
| Vice President of Finance | no data | sin datos | sin datos | |
| Assistant Controller | no data | sin datos | sin datos |
6.3yrs
Permanencia media
49yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de NAGE es experimentado (6.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Chairman | 26.3yrs | US$268.08k | 2.91% $ 8.7m | |
| CEO & Director | 10.8yrs | US$8.38m | 2.09% $ 6.3m | |
| Member of Scientific Advisory Board | 8.9yrs | sin datos | sin datos | |
| Lead Independent Director | 9.2yrs | US$293.08k | 0.0088% $ 26.2k | |
| Chairman of the Scientific Advisory Board | 11.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 11.7yrs | sin datos | sin datos | |
| Independent Director | 4.1yrs | US$265.58k | 0% $ 0 | |
| Non-Executive Director | 8.8yrs | US$243.08k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$258.08k | 0% $ 0 | |
| Chief Scientific Advisor & Member of Scientific Advisory Board | 11.7yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | 6.8yrs | sin datos | sin datos | |
| Non-Executive Director | 4.4yrs | US$245.58k | 0% $ 0 |
9.0yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de NAGE se considera experimentada (9 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 09:00 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Niagen Bioscience, Inc. está cubierta por 8 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Susan Anderson | Canaccord Genuity |
| Jeffrey Mark | Farmhouse Equity Research |